What are Orexin Receptor Antagonist [EPC] drugs?

Orexin Receptor Antagonist [EPC] drugs are pharmacologic agents that share a common mechanism (typically targeting Orexin receptor type 2). 3 are currently marketed, with 10 more in clinical development.

What are the marketed Orexin Receptor Antagonist [EPC] drugs?

Marketed Orexin Receptor Antagonist [EPC] drugs include Dayvigo, Quviviq, Suvorexant (Belsomra).

Orexin Receptor Antagonist [EPC]

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3 marketed 3 in Phase 3 7 in Phase 2

This page covers all Orexin Receptor Antagonist [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Orexin receptor type 2, Orexin receptor type 1, Orexin receptor 1 (OX1R) and Orexin receptor 2 (OX2R).

Targets

Orexin receptor type 2 · Orexin receptor type 1 · Orexin receptor 1 (OX1R) and Orexin receptor 2 (OX2R) · OX1R and OX2R (orexin receptors 1 and 2) · OX1R and OX2R (orexin receptors) · Orexin receptor · orexin receptor

Marketed (3)

Dayvigo · Eisai · Neuroscience
Dayvigo blocks the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles.
Quviviq · Idorsia · Neuroscience
Quviviq works by blocking the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles.
Suvorexant (Belsomra) · Massachusetts General Hospital · Neurology / Sleep Medicine
Suvorexant blocks orexin receptors in the brain to reduce wakefulness and promote sleep.

Phase 3 pipeline (3)

Suvorexant High Dose (HD) · Merck Sharp & Dohme LLC · Neurology / Sleep Medicine
Suvorexant is an orexin receptor antagonist that blocks wake-promoting signals in the brain to promote sleep onset and maintenance.
Suvorexant Low Dose (LD) · Merck Sharp & Dohme LLC · Neurology / Sleep Medicine
Suvorexant is an orexin receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain.
Dose-matched Placebo to Suvorexant · Merck Sharp & Dohme LLC · Neurology / Sleep Medicine
This is a placebo control formulation matched to suvorexant, an orexin receptor antagonist used to promote sleep.

Phase 2 pipeline (7)

AD504 · Apnimed · Neurology
AD504 is an oral small molecule that targets the orexin receptor to treat narcolepsy.
ACT-541468 · Idorsia Pharmaceuticals Ltd. · Sleep disorders
ACT-541468 is a selective orexin receptor antagonist.
Lemborexant tablets · Shanghai Mental Health Center · Neurology
Treats insomnia by modulating orexin receptors
AD036 · Apnimed · Neurology
AD036 is a small molecule that targets the orexin receptor to treat narcolepsy.
AD109 dose1- A · Apnimed · Neurology
AD109 is a small molecule that targets the orexin receptor to treat narcolepsy.
AD182 · Apnimed · Neurology
AD182 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.
AD109 dose2- B · Apnimed · Neurology
AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.

Patent intelligence

orexin receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates